ĐÁNH GIÁ HIỆU QUẢ CỦA PHÁC ĐỒ PACLITAXEL + CARBOPLATIN TRONG ĐIỀU TRỊ BƯỚC 1 UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV

Abstract

Objectives: Evaluation the treatment outcomes of first-line chemotherapy with Paclitaxel – Carboplatin in patients with stage IV non-small cell lung cancer (NSCLC). Study subjects: 42 patients with stage IV NSCLC received first-line chemotherapy with Paclitaxel – Carboplatin at Oncology Center – Military Hospital 103 and Cancer Department– National Lung Hospital from January 2018 to December 2021. Methods: A retrospective combined with prospective descriptive study, cross sectional and interventional study without concurrent control. Results:  The average age of patients enrolled in this study was 58,7 ± 9,1. The male/female ratio was 3.2/1. Adenocarcinoma was accounting for 69%. Most patients were at stage IVA, accounting for 74%. The functional response rate was 68,5%. The overall response rate was 33.4% and the disease control rate was 69%. Post-treatment serum CEA was 7,95 ± 6,22 ng/mL and  significantly lower than pre-treatment serum CEA was 14,73 ± with p 0,013 < 0.05. Median progression-free survival (PFS) was 6,0 months (5,7-6,3), median overall survival (OS) was 11,1 months (8,6 – 13,5). Most toxicity is at low level and controllable. Conclusions: First-line chemotherapy with Paclitaxel – Carboplatin regimen in the treatment of patients with stage IV NSCLC improves functional symtoms, disease response and control rate, PFS and OS with acceptable toxicity.